JP Morgan Chase
BLTE

JP Morgan Chase’s Belite Bio BLTE Stock Holding History

JP Morgan Chase’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.13M Buy
33,181
+33,178
+1,105,933% +$5.09M ﹤0.01% 3426
2026
Q1 		$448 Hold
3
– – ﹤0.01% 7187
2025
Q4 		$480 Sell
3
-9,806
-100% -$1.16M ﹤0.01% 7084
2025
Q3 		$726K Buy
9,809
+3,052
+45% +$200K ﹤0.01% 4813
2025
Q2 		$390K Sell
6,757
-1,405
-17% -$85.7K ﹤0.01% 4905
2025
Q1 		$540K Sell
8,162
-6,474
-44% -$390K ﹤0.01% 4717
2024
Q4 		$924K Buy
14,636
+8,280
+130% +$546K ﹤0.01% 4696
2024
Q3 		$298K Buy
6,356
+6,268
+7,123% +$304K ﹤0.01% 5208
2024
Q2 		$4.02K Sell
88
-570
-87% -$24.7K ﹤0.01% 6424
2024
Q1 		$25.2K Sell
658
-13,609
-95% -$609K ﹤0.01% 6163
2023
Q4 		$653K Buy
+14,267
New +$548K ﹤0.01% 4619
2022
Q4 		– Sell
-7,400
Closed -$250K – 6554
2022
Q3 		$250K Buy
+7,400
New +$256K ﹤0.01% 4840

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase's BLTE Position: Q2 2026 in Review

JP Morgan Chase increased its Belite Bio (BLTE) stake by 1,105,933% in Q2 2026, buying an estimated $5.09M and bringing the position to 33,181 shares worth $5.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3426.

JP Morgan Chase first reported a position in BLTE in Q3 2022 and has held it in 12 quarters since. 80 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • JP Morgan Chase held 33,181 shares of Belite Bio worth $5.13M as of Q2 2026.
  • JP Morgan Chase bought 33,178 Belite Bio shares in Q2 2026, an estimated $5.09M.
  • Belite Bio made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3426 holding.
  • JP Morgan Chase first reported a position in Belite Bio in Q3 2022 and has held it in 12 quarters since.
  • 80 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.